Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile

Affiliations

¹ Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
² Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Comment

Luigino Calzetta et al. Expert Rev Respir Med. 2021 Apr.

. 2021 Apr;15(4):579-581.

doi: 10.1080/17476348.2021.1866835. Epub 2020 Dec 28.

¹ Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
² Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

No abstract available

Comment on

Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies.
Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Calzetta L, et al. Expert Rev Respir Med. 2021 Jan;15(1):143-152. doi: 10.1080/17476348.2020.1816830. Epub 2020 Sep 14. Expert Rev Respir Med. 2021. PMID: 32856967
Reply to: 'evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies'.
Han MK, Lipson DA, Singh D, Martinez FJ. Han MK, et al. Expert Rev Respir Med. 2021 Apr;15(4):577-578. doi: 10.1080/17476348.2021.1865813. Epub 2020 Dec 28. Expert Rev Respir Med. 2021. PMID: 33336588 No abstract available.